Monk, B.J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.S. and Oaknin, A. (2013) A Phase III, Randomized, Double-Blind Trial of Weekly Paclitaxel plus the Angiopoietin 1 and 2 Inhibitor, Trebananib or Placebo in Women with Recurrent Ovarian Cancer: TRINOVA-1. European Journal of Cancer, 49.

has been cited by the following article:

• TITLE: Current Possible Drug Therapies for Ovarian Cancer

  AUTHORS: Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim

  KEYWORDS: Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.13, November 7, 2014

  ABSTRACT: Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cytoreductive therapy followed by molecular targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is a hot therapeutic concept in ovarian cancers. In our review, we will introduce recent therapeutic advances in epithelial ovarian cancer patients.